Martin Šmakal
- Oncology top 1%
- Colorectal Cancer Treatments and Studies 9
- Lung Cancer Research Studies 5
- Neutropenia and Cancer Infections 5
- Cancer Treatment and Pharmacology 4
- Hepatology top 2%
-
- Lung Cancer Treatments and Mutations 8
- Cancer Research top 5%
-
- Blood disorders and treatments 4
-
- Erythropoietin and Anemia Treatment 4
-
- Biosimilars and Bioanalytical Methods 4
- Co-authors
- David CunninghamYves HumbletIlona KocákováFernando RiveraJosep TaberneroMario BarugelJean‐Yves DouillardMaria Błasińska-Morawiec
- Journals
- Journal of Clinical Oncology (7 papers)Annals of Oncology (6 papers)European Journal of Cancer (1 paper)
- Partner nations
- United StatesSpainBelgium
In The Last Decade
Martin Šmakal
26 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 84
- Oncology 2.1k
- Hepatology 385
- Pulmonary and Respiratory Medicine 896
- Cancer Research 378
- Pathology and Forensic Medicine 423
Countries citing papers authored by Martin Šmakal
This map shows the geographic impact of Martin Šmakal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Šmakal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Šmakal more than expected).
Fields of papers citing papers by Martin Šmakal
This network shows the impact of papers produced by Martin Šmakal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Šmakal. The network helps show where Martin Šmakal may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Martin Šmakal, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 5 | |
| 2 | 2019 | 49 | |
| 3 | 2019 | 17 | |
| 4 | 2018 | 2 | |
| 5 | 2018 | 6 | |
| 6 | 2017 | 1 | |
| 7 | 2017 | 1 | |
| 8 | 2017 | 3 | |
| 9 | Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor studybreakdown → | 2017 | 581 |
| 10 | 2015 | 2 | |
| 11 | 2014 | 89 | |
| 12 | 2014 | 1 | |
| 13 | 2013 | 25 | |
| 14 | 2013 | 2 | |
| 15 | 2013 | 42 | |
| 16 | Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Studybreakdown → | 2010 | 1351 |
| 17 | 2008 | 4 | |
| 18 | 2005 | 6 | |
| 19 | 2004 | 194 | |
| 20 | 1999 | 33 |
About Martin Šmakal
Martin Šmakal is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine, having authored 26 papers that have together received 2.6k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (9 papers), Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (5 papers), Neutropenia and Cancer Infections (5 papers), Blood disorders and treatments (4 papers), Cancer Treatment and Pharmacology (4 papers), Erythropoietin and Anemia Treatment (4 papers) and Biosimilars and Bioanalytical Methods (4 papers). The work is most often cited by research in Oncology (2.1k citations), Hepatology (385 citations) and Pulmonary and Respiratory Medicine (896 citations). Martin Šmakal has collaborated with scholars based in United States, Spain and Belgium. Frequent co-authors include David Cunningham, Yves Humblet, Ilona Kocáková, Fernando Rivera, Josep Tabernero, Mario Barugel, Jean‐Yves Douillard, Maria Błasińska-Morawiec, Paul Ruff and Ronald L. Burkes. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.